Identification

Name
Thiamylal
Accession Number
DB01154  (APRD00154)
Type
Small Molecule
Groups
Approved, Vet approved
Description

A barbiturate that is administered intravenously for the production of complete anesthesia of short duration, for the induction of general anesthesia, or for inducing a hypnotic state. (From Martindale, The Extra Pharmacopoeia, 30th ed, p919)

Structure
Thumb
Synonyms
  • 5-Allyl-5-(1-methylbutyl)-2-thiobarbituric acid
  • 5-Allyl-5-(1-methylbutyl)-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione
  • 5-Allyl-5-(1-methylbutyl)-2-thioxodihydropyrimidine-4,6(1H,5H)-dione
  • dihydro-5-(1-Methylbutyl)-5-(2-propenyl)-2-thioxo-4,6(1H,5H)-pyrimidinedione
  • Thiamylal
  • Thioseconal
Product Ingredients
IngredientUNIICASInChI Key
Thiamylal sodiumT4L2P3KH7K337-47-3LYZGJWXNOGIVQA-UHFFFAOYSA-M
International/Other Brands
Surital / Thioseconal
Categories
UNII
01T23W89FR
CAS number
77-27-0
Weight
Average: 254.349
Monoisotopic: 254.10889852
Chemical Formula
C12H18N2O2S
InChI Key
XLOMZPUITCYLMJ-UHFFFAOYSA-N
InChI
InChI=1S/C12H18N2O2S/c1-4-6-8(3)12(7-5-2)9(15)13-11(17)14-10(12)16/h5,8H,2,4,6-7H2,1,3H3,(H2,13,14,15,16,17)
IUPAC Name
5-(pentan-2-yl)-5-(prop-2-en-1-yl)-2-sulfanylidene-1,3-diazinane-4,6-dione
SMILES
CCCC(C)C1(CC=C)C(=O)NC(=S)NC1=O

Pharmacology

Indication

Used for the production of complete anaesthesia of short duration, for the induction of general anaesthesia, and for inducing a hypnotic state.

Pharmacodynamics

Thiamylal, a barbiturate, is used in combination with acetaminophen or aspirin and caffeine for its sedative and relaxant effects in the treatment of tension headaches, migraines, and pain. Barbiturates act as nonselective depressants of the central nervous system (CNS), capable of producing all levels of CNS mood alteration from excitation to mild sedation, hypnosis, and deep coma. In sufficiently high therapeutic doses, barbiturates induce anesthesia.

Mechanism of action

Thiamylal binds at a distinct binding site associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.

TargetActionsOrganism
AGamma-aminobutyric acid receptor subunit alpha-1
agonist
Human
AATP-sensitive inward rectifier potassium channel 8
inhibitor
Human
AATP-sensitive inward rectifier potassium channel 11
inhibitor
Human
Absorption

Rapidly absorbed (high lipid solubility).

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Hepatic.

Route of elimination
Not Available
Half life

Although no studies have been performed on humans, the half-life in cats is 14.3 hours.

Clearance
Not Available
Toxicity

Intravenous LD50 in rat is 51 mg/kg.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when Thiamylal is combined with 7-Nitroindazole.Experimental
AbirateroneThe metabolism of Thiamylal can be decreased when combined with Abiraterone.Approved
AcebutololThe serum concentration of Acebutolol can be decreased when it is combined with Thiamylal.Approved, Investigational
AcenocoumarolThe metabolism of Acenocoumarol can be increased when combined with Thiamylal.Approved, Investigational
AcepromazineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Aceprometazine.Approved
AcetaminophenThe metabolism of Acetaminophen can be increased when combined with Thiamylal.Approved
Acetyl sulfisoxazoleThe metabolism of Thiamylal can be decreased when combined with Acetyl sulfisoxazole.Approved, Vet Approved
AdipiplonThe risk or severity of adverse effects can be increased when Thiamylal is combined with Adipiplon.Investigational
AgmatineThe metabolism of Agmatine can be increased when combined with Thiamylal.Experimental, Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Thiamylal is combined with Alaproclate.Experimental
AldesleukinThiamylal may increase the hypotensive activities of Aldesleukin.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Thiamylal.Approved, Illicit
AliskirenThiamylal may increase the hypotensive activities of Aliskiren.Approved, Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Thiamylal is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Thiamylal.Approved, Illicit, Investigational
AlprenololThe serum concentration of Alprenolol can be decreased when it is combined with Thiamylal.Approved, Withdrawn
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Thiamylal.Experimental, Investigational
AmifostineThiamylal may increase the hypotensive activities of Amifostine.Approved, Investigational
AmikacinThe risk or severity of adverse effects can be increased when Thiamylal is combined with Amikacin.Approved, Investigational, Vet Approved
AmilorideThiamylal may increase the hypotensive activities of Amiloride.Approved
AmineptineThe metabolism of Amineptine can be increased when combined with Thiamylal.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Thiamylal.Approved
AmiodaroneThiamylal may increase the hypotensive activities of Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Thiamylal is combined with Amisulpride.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be increased when combined with Thiamylal.Approved
AmitriptylinoxideThe metabolism of Amitriptylinoxide can be increased when combined with Thiamylal.Approved, Investigational
AmlodipineThiamylal may increase the hypotensive activities of Amlodipine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Thiamylal.Approved, Illicit
AmoxapineThe metabolism of Amoxapine can be increased when combined with Thiamylal.Approved
AmperozideThe risk or severity of adverse effects can be increased when Thiamylal is combined with Amperozide.Experimental
Amphotericin BThiamylal may increase the hypotensive activities of Amphotericin B.Approved, Investigational
AmrinoneThe metabolism of Amrinone can be increased when combined with Thiamylal.Approved
Amyl NitriteThiamylal may increase the hypotensive activities of Amyl Nitrite.Approved
ApalutamideThe serum concentration of Thiamylal can be decreased when it is combined with Apalutamide.Approved, Investigational
ApomorphineThiamylal may increase the hypotensive activities of Apomorphine.Approved, Investigational
ApraclonidineThiamylal may increase the hypotensive activities of Apraclonidine.Approved
AprepitantThe metabolism of Thiamylal can be increased when combined with Aprepitant.Approved, Investigational
AranidipineThe metabolism of Aranidipine can be increased when combined with Thiamylal.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Thiamylal.Approved, Investigational
ArotinololThe serum concentration of Arotinolol can be decreased when it is combined with Thiamylal.Investigational
Arsenic trioxideThiamylal may increase the hypotensive activities of Arsenic trioxide.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Thiamylal.Approved
AtenololThe serum concentration of Atenolol can be decreased when it is combined with Thiamylal.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Azaperone.Investigational, Vet Approved
AzelastineThiamylal may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelnidipineThe metabolism of Azelnidipine can be increased when combined with Thiamylal.Approved, Investigational
Azilsartan medoxomilThiamylal may increase the hypotensive activities of Azilsartan medoxomil.Approved, Investigational
AzimilideThe metabolism of Azimilide can be increased when combined with Thiamylal.Investigational
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Thiamylal.Approved
BarbitalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Barbital.Illicit
BarnidipineThiamylal may increase the hypotensive activities of Barnidipine.Approved
BefunololThe serum concentration of Befunolol can be decreased when it is combined with Thiamylal.Experimental
BenazeprilThiamylal may increase the hypotensive activities of Benazepril.Approved, Investigational
BencyclaneThe metabolism of Bencyclane can be increased when combined with Thiamylal.Experimental
BendroflumethiazideThiamylal may increase the orthostatic hypotensive activities of Bendroflumethiazide.Approved
BenidipineThe metabolism of Benidipine can be increased when combined with Thiamylal.Approved, Investigational
BenperidolThe risk or severity of adverse effects can be increased when Thiamylal is combined with Benperidol.Approved, Investigational
BenzphetamineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Benzphetamine.Approved, Illicit
BenzthiazideThiamylal may increase the orthostatic hypotensive activities of Benzthiazide.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Thiamylal is combined with Benzyl alcohol.Approved
BepridilThiamylal may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololThe serum concentration of Betaxolol can be decreased when it is combined with Thiamylal.Approved, Investigational
BevantololThe serum concentration of Bevantolol can be decreased when it is combined with Thiamylal.Approved
BioallethrinThe metabolism of Bioallethrin can be increased when combined with Thiamylal.Approved, Experimental
BisoprololThe serum concentration of Bisoprolol can be decreased when it is combined with Thiamylal.Approved
BopindololThe serum concentration of Bopindolol can be decreased when it is combined with Thiamylal.Approved
BortezomibThiamylal may increase the hypotensive activities of Bortezomib.Approved, Investigational
BretyliumThiamylal may increase the hypotensive activities of Bretylium.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Thiamylal.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Thiamylal.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Thiamylal.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Bromisoval.Experimental
BromocriptineThiamylal may increase the hypotensive activities of Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Thiamylal is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Thiamylal.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Thiamylal is combined with Brotizolam.Approved, Investigational, Withdrawn
BucindololThe serum concentration of Bucindolol can be decreased when it is combined with Thiamylal.Investigational
BufuralolThe serum concentration of Bufuralol can be decreased when it is combined with Thiamylal.Experimental, Investigational
BumetanideThiamylal may increase the hypotensive activities of Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Thiamylal.Approved, Investigational
BupranololThe serum concentration of Bupranolol can be decreased when it is combined with Thiamylal.Approved
BuprenorphineThiamylal may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Thiamylal is combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Thiamylal.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Thiamylal.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Thiamylal.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Thiamylal is combined with Butamben.Approved, Withdrawn
ButethalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Thiamylal.Approved, Illicit, Vet Approved
ButriptylineThe metabolism of Butriptyline can be increased when combined with Thiamylal.Approved
CaffeineThe serum concentration of Caffeine can be decreased when it is combined with Thiamylal.Approved
CanagliflozinThiamylal may increase the hypotensive activities of Canagliflozin.Approved
Candesartan cilexetilThiamylal may increase the hypotensive activities of Candesartan cilexetil.Approved
CanertinibThe risk or severity of adverse effects can be increased when Thiamylal is combined with Canertinib.Investigational
CapecitabineThe metabolism of Thiamylal can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThiamylal may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe metabolism of Thiamylal can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThiamylal may increase the hypotensive activities of Carbetocin.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Thiamylal.Approved
CarboxyamidotriazoleThe metabolism of Carboxyamidotriazole can be increased when combined with Thiamylal.Investigational
CarfentanilThe risk or severity of adverse effects can be increased when Thiamylal is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Thiamylal.Approved
CaroverineThe metabolism of Caroverine can be increased when combined with Thiamylal.Experimental
CarteololThe serum concentration of Carteolol can be decreased when it is combined with Thiamylal.Approved
CarvedilolThiamylal may increase the hypotensive activities of Carvedilol.Approved, Investigational
CeliprololThe serum concentration of Celiprolol can be decreased when it is combined with Thiamylal.Approved, Investigational
CeritinibThe serum concentration of Thiamylal can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Thiamylal.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Thiamylal is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChloramphenicolThe metabolism of Thiamylal can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Thiamylal.Approved, Illicit, Investigational
ChlormadinoneThe therapeutic efficacy of Chlormadinone can be decreased when used in combination with Thiamylal.Experimental
ChlormezanoneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Chloroprocaine.Approved
ChlorothiazideThiamylal may increase the orthostatic hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Thiamylal.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Thiamylal.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorthalidoneThiamylal may increase the orthostatic hypotensive activities of Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Thiamylal.Approved
CholecalciferolThe metabolism of Thiamylal can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CilazaprilThiamylal may increase the hypotensive activities of Cilazapril.Approved
CilnidipineThiamylal may increase the hypotensive activities of Cilnidipine.Approved, Investigational
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Thiamylal.Approved, Vet Approved
CinnarizineThe metabolism of Cinnarizine can be increased when combined with Thiamylal.Approved, Investigational
CitalopramThe risk or severity of adverse effects can be increased when Thiamylal is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Thiamylal.Approved, Investigational
ClevidipineThiamylal may increase the hypotensive activities of Clevidipine.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Thiamylal.Approved
ClindamycinThe risk or severity of adverse effects can be increased when Thiamylal is combined with Clindamycin.Approved, Vet Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Thiamylal.Approved, Illicit
ClofarabineThiamylal may increase the hypotensive activities of Clofarabine.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when Thiamylal is combined with clomethiazole.Investigational
ClomipramineThe metabolism of Clomipramine can be increased when combined with Thiamylal.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Thiamylal.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Thiamylal.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Thiamylal is combined with Clopenthixol.Experimental
CloranololThe serum concentration of Cloranolol can be decreased when it is combined with Thiamylal.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Thiamylal.Approved, Illicit
ClorindioneThe metabolism of Clorindione can be increased when combined with Thiamylal.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Thiamylal can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Thiamylal.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Thiamylal.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Thiamylal.Approved, Illicit
ConivaptanThiamylal may increase the hypotensive activities of Conivaptan.Approved, Investigational
CrisaboroleThe metabolism of Thiamylal can be decreased when combined with Crisaborole.Approved, Investigational
CurcuminThe metabolism of Thiamylal can be decreased when combined with Curcumin.Approved, Investigational
CyclandelateThe metabolism of Cyclandelate can be increased when combined with Thiamylal.Approved
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Thiamylal.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be increased when combined with Thiamylal.Approved
CyclopenthiazideThiamylal may increase the orthostatic hypotensive activities of Cyclopenthiazide.Experimental
CyclopropaneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Cyclopropane.Experimental
CyclosporineThe metabolism of Cyclosporine can be increased when combined with Thiamylal.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Thiamylal.Approved
Cyproterone acetateThe therapeutic efficacy of Cyproterone acetate can be decreased when used in combination with Thiamylal.Approved, Investigational
DabrafenibThe serum concentration of Thiamylal can be decreased when it is combined with Dabrafenib.Approved, Investigational
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Thiamylal.Approved, Investigational
DapagliflozinThiamylal may increase the hypotensive activities of Dapagliflozin.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Thiamylal.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Dapoxetine.Investigational
DarodipineThe metabolism of Darodipine can be increased when combined with Thiamylal.Experimental
DelavirdineThe metabolism of Thiamylal can be decreased when combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Thiamylal.Approved
DesipramineThe metabolism of Desipramine can be increased when combined with Thiamylal.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Thiamylal.Approved, Investigational
DesogestrelThe therapeutic efficacy of Desogestrel can be decreased when used in combination with Thiamylal.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Detomidine.Vet Approved
DeutetrabenazineThe risk or severity of sedation and somnolence can be increased when Thiamylal is combined with Deutetrabenazine.Approved, Investigational
DexamethasoneThe serum concentration of Thiamylal can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Thiamylal.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Thiamylal.Approved, Vet Approved
DexniguldipineThe metabolism of Dexniguldipine can be increased when combined with Thiamylal.Experimental
DextromoramideThe risk or severity of adverse effects can be increased when Thiamylal is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Thiamylal.Approved, Illicit, Investigational, Withdrawn
DexverapamilThe metabolism of Dexverapamil can be increased when combined with Thiamylal.Experimental
DezocineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Thiamylal.Approved, Illicit, Investigational, Vet Approved
DibenzepinThe metabolism of Dibenzepin can be increased when combined with Thiamylal.Experimental
DiclofenamideThiamylal may increase the hypotensive activities of Diclofenamide.Approved, Investigational
DicoumarolThe metabolism of Dicoumarol can be increased when combined with Thiamylal.Approved
DienogestThe therapeutic efficacy of Dienogest can be decreased when used in combination with Thiamylal.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Thiamylal is combined with Diethyl ether.Experimental
DiethylstilbestrolThe therapeutic efficacy of Diethylstilbestrol can be decreased when used in combination with Thiamylal.Approved, Investigational
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Thiamylal.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Thiamylal.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThiamylal may increase the hypotensive activities of Diltiazem.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Thiamylal.Approved
DimetacrineThe metabolism of Dimetacrine can be increased when combined with Thiamylal.Approved, Withdrawn
DinutuximabThiamylal may increase the hypotensive activities of Dinutuximab.Approved, Investigational
DiphenadioneThe metabolism of Diphenadione can be increased when combined with Thiamylal.Experimental
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Thiamylal.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Thiamylal.Approved, Illicit
DipyridamoleThiamylal may increase the hypotensive activities of Dipyridamole.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Thiamylal is combined with Doramectin.Vet Approved
DosulepinThe metabolism of Dosulepin can be increased when combined with Thiamylal.Approved
DotarizineThe metabolism of Dotarizine can be increased when combined with Thiamylal.Investigational
DoxazosinThiamylal may increase the hypotensive activities of Doxazosin.Approved
DoxepinThe metabolism of Doxepin can be increased when combined with Thiamylal.Approved, Investigational
DoxycyclineThe serum concentration of Doxycycline can be decreased when it is combined with Thiamylal.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Thiamylal.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Thiamylal is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Thiamylal.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Thiamylal.Approved, Vet Approved
DrospirenoneThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Thiamylal.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Thiamylal is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Thiamylal.Approved
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Thiamylal.Approved
EcgonineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Thiamylal is combined with Ecopipam.Investigational
EfavirenzThe metabolism of Thiamylal can be decreased when combined with Efavirenz.Approved, Investigational
EfonidipineThiamylal may increase the hypotensive activities of Efonidipine.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Eltanolone.Investigational
EmopamilThe metabolism of Emopamil can be increased when combined with Thiamylal.Experimental
EmpagliflozinThiamylal may increase the hypotensive activities of Empagliflozin.Approved
EnalaprilThiamylal may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatThiamylal may increase the hypotensive activities of Enalaprilat.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Thiamylal.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Thiamylal.Approved, Investigational
EpanololThe serum concentration of Epanolol can be decreased when it is combined with Thiamylal.Experimental
EperisoneThe metabolism of Eperisone can be increased when combined with Thiamylal.Approved, Investigational
EpitizideThiamylal may increase the orthostatic hypotensive activities of Epitizide.Experimental
EplerenoneThiamylal may increase the hypotensive activities of Eplerenone.Approved
EpoprostenolThiamylal may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThiamylal may increase the hypotensive activities of Eprosartan.Approved
EsatenololThe serum concentration of Esatenolol can be decreased when it is combined with Thiamylal.Experimental
EscitalopramThe risk or severity of adverse effects can be increased when Thiamylal is combined with Escitalopram.Approved, Investigational
EsmololThe serum concentration of Esmolol can be decreased when it is combined with Thiamylal.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Thiamylal.Approved, Illicit
EstradiolThe therapeutic efficacy of Estradiol can be decreased when used in combination with Thiamylal.Approved, Investigational, Vet Approved
Estradiol cypionateThe therapeutic efficacy of Estradiol cypionate can be decreased when used in combination with Thiamylal.Approved, Investigational, Vet Approved
Estradiol valerateThe therapeutic efficacy of Estradiol valerate can be decreased when used in combination with Thiamylal.Approved, Investigational, Vet Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Thiamylal.Approved, Investigational
Etacrynic acidThiamylal may increase the hypotensive activities of Etacrynic acid.Approved, Investigational
EthanolThiamylal may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Thiamylal.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe therapeutic efficacy of Ethinyl Estradiol can be decreased when used in combination with Thiamylal.Approved
EthosuximideThe metabolism of Ethosuximide can be increased when combined with Thiamylal.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Thiamylal.Approved
Ethyl biscoumacetateThe metabolism of Ethyl biscoumacetate can be increased when combined with Thiamylal.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Thiamylal is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Thiamylal is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Thiamylal is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Ethylmorphine.Approved, Illicit
Ethynodiol diacetateThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Thiamylal.Approved
EtidocaineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Thiamylal is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Thiamylal.Approved
EtonogestrelThe therapeutic efficacy of Etonogestrel can be decreased when used in combination with Thiamylal.Approved, Investigational
EtoperidoneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Etorphine.Illicit, Vet Approved
EtravirineThe metabolism of Thiamylal can be decreased when combined with Etravirine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Thiamylal.Approved, Investigational
FelbamateThe serum concentration of Thiamylal can be increased when it is combined with Felbamate.Approved
FelodipineThiamylal may increase the hypotensive activities of Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Fencamfamine.Approved, Illicit, Withdrawn
FendilineThe metabolism of Fendiline can be increased when combined with Thiamylal.Withdrawn
FenoldopamThiamylal may increase the hypotensive activities of Fenoldopam.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Thiamylal.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Thiamylal.Approved, Investigational
FimasartanThiamylal may increase the hypotensive activities of Fimasartan.Approved, Investigational
Fish oilThe metabolism of Fish oil can be increased when combined with Thiamylal.Approved, Nutraceutical
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Thiamylal.Approved, Investigational
FloxuridineThe metabolism of Thiamylal can be decreased when combined with Floxuridine.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Fluanisone.Experimental
FluconazoleThe metabolism of Thiamylal can be decreased when combined with Fluconazole.Approved, Investigational
FludiazepamThe risk or severity of adverse effects can be increased when Thiamylal is combined with Fludiazepam.Approved, Illicit
FluindioneThe metabolism of Fluindione can be increased when combined with Thiamylal.Approved, Investigational
FlunarizineThe metabolism of Flunarizine can be increased when combined with Thiamylal.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Thiamylal is combined with Flunitrazepam.Approved, Illicit
FluorouracilThe metabolism of Thiamylal can be decreased when combined with Fluorouracil.Approved
FluoxetineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Thiamylal.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Thiamylal.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Thiamylal.Approved, Illicit, Investigational
FluspirileneThe metabolism of Fluspirilene can be increased when combined with Thiamylal.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Thiamylal.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Fluvoxamine.Approved, Investigational
FosinoprilThiamylal may increase the hypotensive activities of Fosinopril.Approved
FosphenytoinThe metabolism of Thiamylal can be increased when combined with Fosphenytoin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Thiamylal is combined with Fospropofol.Approved, Illicit, Investigational
FurosemideThiamylal may increase the hypotensive activities of Furosemide.Approved, Vet Approved
GabapentinThe metabolism of Gabapentin can be increased when combined with Thiamylal.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Thiamylal.Approved, Investigational
GallopamilThe metabolism of Gallopamil can be increased when combined with Thiamylal.Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Thiamylal.Approved, Illicit, Investigational
GanciclovirThe serum concentration of Ganciclovir can be decreased when it is combined with Thiamylal.Approved, Investigational
GemfibrozilThe metabolism of Thiamylal can be decreased when combined with Gemfibrozil.Approved
GepironeThe risk or severity of adverse effects can be increased when Thiamylal is combined with Gepirone.Investigational
GestodeneThe therapeutic efficacy of Gestodene can be decreased when used in combination with Thiamylal.Approved, Investigational
GestrinoneThe therapeutic efficacy of Gestrinone can be decreased when used in combination with Thiamylal.Approved
GlutethimideThe risk or severity of adverse effects can be increased when Thiamylal is combined with Glutethimide.Approved, Illicit
GriseofulvinThe serum concentration of Griseofulvin can be decreased when it is combined with Thiamylal.Approved, Investigational, Vet Approved
GuanfacineThiamylal may increase the hypotensive activities of Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Thiamylal.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Thiamylal.Approved
HalothaneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Thiamylal is combined with Heroin.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Hexobarbital.Approved
HydralazineThiamylal may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideThe risk or severity of hypotension and orthostatic hypotension can be increased when Thiamylal is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThiamylal may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThiamylal may increase the orthostatic hypotensive activities of Hydroflumethiazide.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Thiamylal.Approved, Illicit
Hydroxyprogesterone caproateThe therapeutic efficacy of Hydroxyprogesterone caproate can be decreased when used in combination with Thiamylal.Approved, Investigational
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Thiamylal.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Thiamylal.Approved
IloprostThiamylal may increase the hypotensive activities of Iloprost.Approved, Investigational
ImidaprilThiamylal may increase the hypotensive activities of Imidapril.Investigational
ImipramineThe metabolism of Imipramine can be increased when combined with Thiamylal.Approved
IndalpineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Indalpine.Investigational, Withdrawn
IndapamideThiamylal may increase the orthostatic hypotensive activities of Indapamide.Approved
IndenololThe serum concentration of Indenolol can be decreased when it is combined with Thiamylal.Withdrawn
IndinavirThe metabolism of Thiamylal can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Thiamylal is combined with Indiplon.Investigational
IndoraminThiamylal may increase the hypotensive activities of Indoramin.Withdrawn
IprindoleThe metabolism of Iprindole can be increased when combined with Thiamylal.Experimental
IrbesartanThe metabolism of Thiamylal can be decreased when combined with Irbesartan.Approved, Investigational
IsocarboxazidThiamylal may increase the hypotensive activities of Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Thiamylal.Approved, Vet Approved
Isosorbide DinitrateThiamylal may increase the hypotensive activities of Isosorbide Dinitrate.Approved, Investigational
Isosorbide MononitrateThiamylal may increase the hypotensive activities of Isosorbide Mononitrate.Approved
IsoxsuprineThiamylal may increase the hypotensive activities of Isoxsuprine.Approved, Withdrawn
IsradipineThiamylal may increase the hypotensive activities of Isradipine.Approved, Investigational
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Thiamylal.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Thiamylal is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe metabolism of Thiamylal can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolThiamylal may increase the hypotensive activities of Labetalol.Approved
LacidipineThiamylal may increase the hypotensive activities of Lacidipine.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Thiamylal.Approved, Investigational
LandiololThe serum concentration of Landiolol can be decreased when it is combined with Thiamylal.Investigational
LeflunomideThe metabolism of Thiamylal can be decreased when combined with Leflunomide.Approved, Investigational
LercanidipineThiamylal may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevetiracetamThe metabolism of Levetiracetam can be increased when combined with Thiamylal.Approved, Investigational
LevobetaxololThe serum concentration of Levobetaxolol can be decreased when it is combined with Thiamylal.Approved, Investigational
LevobunololThe serum concentration of Levobunolol can be decreased when it is combined with Thiamylal.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Thiamylal.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Thiamylal.Approved
LevodopaThiamylal may increase the hypotensive activities of Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Thiamylal is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Thiamylal is combined with Levomilnacipran.Approved, Investigational
LevonorgestrelThe therapeutic efficacy of Levonorgestrel can be decreased when used in combination with Thiamylal.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Thiamylal.Approved
LevosimendanThiamylal may increase the hypotensive activities of Levosimendan.Approved, Investigational
LidoflazineThe metabolism of Lidoflazine can be increased when combined with Thiamylal.Experimental
LisinoprilThiamylal may increase the hypotensive activities of Lisinopril.Approved, Investigational
Lithium cationThe risk or severity of adverse effects can be increased when Thiamylal is combined with Lithium.Experimental
LobeglitazoneThe metabolism of Thiamylal can be decreased when combined with Lobeglitazone.Approved, Investigational
LofentanilThe risk or severity of adverse effects can be increased when Thiamylal is combined with Lofentanil.Illicit
LofepramineThe metabolism of Lofepramine can be increased when combined with Thiamylal.Experimental
LofexidineThe therapeutic efficacy of Thiamylal can be increased when used in combination with Lofexidine.Approved, Investigational
LomerizineThe metabolism of Lomerizine can be increased when combined with Thiamylal.Experimental
LoperamideThe metabolism of Loperamide can be increased when combined with Thiamylal.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Thiamylal is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Thiamylal.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Thiamylal.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Thiamylal is combined with Lormetazepam.Approved
LosartanThiamylal may increase the hypotensive activities of Losartan.Approved
LovastatinThe metabolism of Thiamylal can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Thiamylal.Approved
LumacaftorThe serum concentration of Thiamylal can be decreased when it is combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Thiamylal.Approved, Investigational
LynestrenolThe therapeutic efficacy of Lynestrenol can be decreased when used in combination with Thiamylal.Approved, Investigational
Magnesium carbonateThe risk or severity of adverse effects can be increased when Thiamylal is combined with Magnesium carbonate.Approved, Investigational
Magnesium citrateThe risk or severity of adverse effects can be increased when Thiamylal is combined with Magnesium citrate.Approved
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Thiamylal is combined with Magnesium hydroxide.Approved, Investigational
Magnesium sulfateThe therapeutic efficacy of Thiamylal can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateThe risk or severity of adverse effects can be increased when Thiamylal is combined with Magnesium Trisilicate.Approved
ManidipineThe metabolism of Manidipine can be increased when combined with Thiamylal.Approved, Investigational
MannitolThiamylal may increase the hypotensive activities of Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Thiamylal.Approved, Investigational
MebicarThe risk or severity of adverse effects can be increased when Thiamylal is combined with Mebicar.Experimental
MecamylamineThiamylal may increase the hypotensive activities of Mecamylamine.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Thiamylal.Approved
MedazepamThe risk or severity of adverse effects can be increased when Thiamylal is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Medetomidine.Vet Approved
MedrogestoneThe serum concentration of Medrogestone can be decreased when it is combined with Thiamylal.Approved
Medroxyprogesterone acetateThe therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Thiamylal.Approved, Investigational
Megestrol acetateThe therapeutic efficacy of Megestrol acetate can be decreased when used in combination with Thiamylal.Approved, Investigational, Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Thiamylal.Approved, Nutraceutical, Vet Approved
MelitracenThe metabolism of Melitracen can be increased when combined with Thiamylal.Experimental, Investigational
MelperoneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Melperone.Approved, Investigational
MentholThe metabolism of Menthol can be increased when combined with Thiamylal.Approved
MepindololThe serum concentration of Mepindolol can be decreased when it is combined with Thiamylal.Experimental
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Thiamylal.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Thiamylal.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Thiamylal is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Thiamylal.Approved, Investigational
MestranolThe therapeutic efficacy of Mestranol can be decreased when used in combination with Thiamylal.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Thiamylal.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Thiamylal.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Thiamylal is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Methaqualone.Illicit, Withdrawn
MethazolamideThiamylal may increase the hypotensive activities of Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Thiamylal.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Thiamylal.Approved
MethotrimeprazineThiamylal may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Thiamylal.Approved, Investigational, Vet Approved
MethsuximideThe metabolism of Methsuximide can be increased when combined with Thiamylal.Approved
MethyclothiazideThiamylal may increase the orthostatic hypotensive activities of Methyclothiazide.Approved
MethyldopaThiamylal may increase the hypotensive activities of Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Methylecgonine.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Thiamylal.Approved
MetipranololThe serum concentration of Metipranolol can be decreased when it is combined with Thiamylal.Approved
MetolazoneThiamylal may increase the orthostatic hypotensive activities of Metolazone.Approved
MetoprololThiamylal may increase the hypotensive activities of Metoprolol.Approved, Investigational
MetyrosineThiamylal may increase the sedative activities of Metyrosine.Approved
MianserinMianserin may increase the central nervous system depressant (CNS depressant) activities of Thiamylal.Approved, Investigational
MibefradilThe metabolism of Mibefradil can be increased when combined with Thiamylal.Investigational, Withdrawn
MiconazoleThe metabolism of Thiamylal can be decreased when combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Thiamylal.Approved, Illicit
MidostaurinThe metabolism of Thiamylal can be decreased when combined with Midostaurin.Approved, Investigational
MifepristoneThe serum concentration of Thiamylal can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Thiamylal is combined with Milnacipran.Approved, Investigational
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Thiamylal.Approved, Investigational
MinoxidilThiamylal may increase the hypotensive activities of Minoxidil.Approved, Investigational
MirtazapineThiamylal may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MoexiprilThiamylal may increase the hypotensive activities of Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Thiamylal.Approved, Investigational
MoxonidineThiamylal may increase the hypotensive activities of Moxonidine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Thiamylal.Approved, Investigational
NadololThe serum concentration of Nadolol can be decreased when it is combined with Thiamylal.Approved
NaftopidilThe metabolism of Naftopidil can be increased when combined with Thiamylal.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Thiamylal.Approved
NebivololThe serum concentration of Nebivolol can be decreased when it is combined with Thiamylal.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Nefazodone.Approved, Withdrawn
NeomycinThe risk or severity of adverse effects can be increased when Thiamylal is combined with Neomycin.Approved, Vet Approved
NesiritideThiamylal may increase the hypotensive activities of Nesiritide.Approved, Investigational
NicardipineThiamylal may increase the hypotensive activities of Nicardipine.Approved, Investigational
NifedipineThiamylal may increase the hypotensive activities of Nifedipine.Approved
NiguldipineThe metabolism of Niguldipine can be increased when combined with Thiamylal.Experimental
NiludipineThe metabolism of Niludipine can be increased when combined with Thiamylal.Experimental
NilvadipineThiamylal may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideThe metabolism of Nimesulide can be increased when combined with Thiamylal.Approved, Investigational, Withdrawn
NimodipineThiamylal may increase the hypotensive activities of Nimodipine.Approved, Investigational
NisoldipineThiamylal may increase the hypotensive activities of Nisoldipine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Thiamylal.Approved
NitrendipineThiamylal may increase the hypotensive activities of Nitrendipine.Approved, Investigational
Nitric OxideThiamylal may increase the hypotensive activities of Nitric Oxide.Approved
NitroglycerinThiamylal may increase the hypotensive activities of Nitroglycerin.Approved, Investigational
NitroprussideThiamylal may increase the hypotensive activities of Nitroprusside.Approved, Investigational
Nitrous acidThiamylal may increase the hypotensive activities of Nitrous acid.Approved, Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Thiamylal.Approved, Vet Approved
Nomegestrol acetateThe therapeutic efficacy of Nomegestrol acetate can be decreased when used in combination with Thiamylal.Approved, Investigational
NordazepamThe risk or severity of adverse effects can be increased when Thiamylal is combined with Nordazepam.Approved
NorelgestrominThe therapeutic efficacy of Norelgestromin can be decreased when used in combination with Thiamylal.Approved, Investigational
NorethisteroneThe therapeutic efficacy of Norethisterone can be decreased when used in combination with Thiamylal.Approved
NorethynodrelThe therapeutic efficacy of Norethynodrel can be decreased when used in combination with Thiamylal.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Norflurane.Approved, Investigational
NorgestimateThe therapeutic efficacy of Norgestimate can be decreased when used in combination with Thiamylal.Approved, Investigational
NorgestrelThe therapeutic efficacy of Norgestrel can be decreased when used in combination with Thiamylal.Approved
NorgestrienoneThe therapeutic efficacy of Norgestrienone can be decreased when used in combination with Thiamylal.Experimental
NormethadoneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Normethadone.Approved, Illicit
NortriptylineThe metabolism of Nortriptyline can be increased when combined with Thiamylal.Approved
NylidrinThe metabolism of Nylidrin can be increased when combined with Thiamylal.Approved
ObinutuzumabThiamylal may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Thiamylal.Approved, Investigational
OlmesartanThiamylal may increase the hypotensive activities of Olmesartan.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Thiamylal.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Thiamylal.Approved
OpipramolThe metabolism of Opipramol can be increased when combined with Thiamylal.Investigational
OpiumThe risk or severity of adverse effects can be increased when Thiamylal is combined with Opium.Approved, Illicit
OrphenadrineThiamylal may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Thiamylal is combined with Osanetant.Investigational
OtiloniumThe metabolism of Otilonium can be increased when combined with Thiamylal.Experimental, Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Thiamylal.Approved
OxprenololThe risk or severity of adverse effects can be increased when Thiamylal is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Thiamylal.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Thiamylal.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Thiamylal.Approved, Investigational, Vet Approved
PaclitaxelThiamylal may increase the hypotensive activities of Paclitaxel.Approved, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Thiamylal.Approved
PapaverineThiamylal may increase the hypotensive activities of Papaverine.Approved, Investigational
ParaldehydeThiamylal may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParomomycinThe risk or severity of adverse effects can be increased when Thiamylal is combined with Paromomycin.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Paroxetine.Approved, Investigational
PenbutololThe serum concentration of Penbutolol can be decreased when it is combined with Thiamylal.Approved, Investigational
PenfluridolThe metabolism of Penfluridol can be increased when combined with Thiamylal.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Thiamylal.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Thiamylal.Approved, Investigational, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Thiamylal.Approved
PerazineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Perazine.Approved, Investigational
PerindoprilThiamylal may increase the hypotensive activities of Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Thiamylal is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Thiamylal.Approved
PethidineThiamylal may increase the central nervous system depressant (CNS depressant) activities of Pethidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Phenazocine.Experimental
PhenelzineThiamylal may increase the hypotensive activities of Phenelzine.Approved
PhenibutThe risk or severity of adverse effects can be increased when Thiamylal is combined with Phenibut.Experimental
PhenindioneThe metabolism of Phenindione can be increased when combined with Thiamylal.Approved, Investigational
PhenobarbitalThe metabolism of Thiamylal can be increased when combined with Phenobarbital.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Phenoperidine.Experimental
PhenoxybenzamineThiamylal may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Thiamylal is combined with Phenoxyethanol.Approved
PhenprocoumonThe metabolism of Phenprocoumon can be increased when combined with Thiamylal.Approved, Investigational
PhentolamineThiamylal may increase the hypotensive activities of Phentolamine.Approved
PhenytoinThe metabolism of Thiamylal can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Thiamylal.Approved
PinaveriumThe metabolism of Pinaverium can be increased when combined with Thiamylal.Approved
PindololThe serum concentration of Pindolol can be decreased when it is combined with Thiamylal.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Thiamylal.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Thiamylal is combined with Piritramide.Approved, Investigational
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Thiamylal.Approved
Platelet Activating FactorThe serum concentration of Platelet Activating Factor can be decreased when it is combined with Thiamylal.Experimental
Polymyxin B SulfateThe risk or severity of adverse effects can be increased when Thiamylal is combined with Polymyxin B Sulfate.Approved, Vet Approved
PolythiazideThiamylal may increase the orthostatic hypotensive activities of Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Thiamylal.Approved
PractololThe serum concentration of Practolol can be decreased when it is combined with Thiamylal.Approved
PramipexoleThiamylal may increase the sedative activities of Pramipexole.Approved, Investigational
PrazepamThe risk or severity of adverse effects can be increased when Thiamylal is combined with Prazepam.Approved, Illicit
PrazosinThiamylal may increase the hypotensive activities of Prazosin.Approved
PregabalinThe therapeutic efficacy of Thiamylal can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrenylamineThe metabolism of Prenylamine can be increased when combined with Thiamylal.Withdrawn
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Thiamylal.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Thiamylal.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Thiamylal.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Thiamylal.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Thiamylal.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Thiamylal.Approved, Investigational
PropacetamolThe metabolism of Propacetamol can be increased when combined with Thiamylal.Approved, Investigational
PropafenoneThe serum concentration of Propafenone can be decreased when it is combined with Thiamylal.Approved
PropanididThe risk or severity of adverse effects can be increased when Thiamylal is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Thiamylal.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Thiamylal.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Propoxycaine.Approved
PropranololThiamylal may increase the hypotensive activities of Propranolol.Approved, Investigational
ProtriptylineThe metabolism of Protriptyline can be increased when combined with Thiamylal.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Thiamylal is combined with PSD502.Investigational
PseudoephedrineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Pseudoephedrine.Approved
PyrantelThe risk or severity of adverse effects can be increased when Thiamylal is combined with Pyrantel.Approved, Vet Approved
PyridoxineThe metabolism of Thiamylal can be increased when combined with Pyridoxine.Approved, Investigational, Nutraceutical, Vet Approved
PyrimethamineThe metabolism of Thiamylal can be decreased when combined with Pyrimethamine.Approved, Investigational, Vet Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Thiamylal.Approved, Illicit
QuetiapineThiamylal may increase the hypotensive activities of Quetiapine.Approved
QuinaprilThiamylal may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinethazoneThiamylal may increase the orthostatic hypotensive activities of Quinethazone.Approved
QuingestanolThe therapeutic efficacy of Quingestanol can be decreased when used in combination with Thiamylal.Experimental
QuinineThe metabolism of Thiamylal can be decreased when combined with Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Thiamylal is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Thiamylal.Approved, Investigational
RamiprilThiamylal may increase the hypotensive activities of Ramipril.Approved
RasagilineThiamylal may increase the hypotensive activities of Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Thiamylal.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Thiamylal.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Thiamylal.Approved, Investigational
RifabutinThe metabolism of Thiamylal can be increased when combined with Rifabutin.Approved, Investigational
RifampicinThe metabolism of Thiamylal can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Thiamylal can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe metabolism of Thiamylal can be increased when combined with Rifaximin.Approved, Investigational
RiociguatThiamylal may increase the hypotensive activities of Riociguat.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Thiamylal.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Thiamylal is combined with Ritanserin.Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Thiamylal is combined with Rizatriptan.Approved
RomifidineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Romifidine.Vet Approved
RopiniroleThiamylal may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Thiamylal.Approved
RotigotineThiamylal may increase the sedative activities of Rotigotine.Approved
RucaparibThe metabolism of Thiamylal can be decreased when combined with Rucaparib.Approved, Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Thiamylal.Approved
SacubitrilThiamylal may increase the hypotensive activities of Sacubitril.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Thiamylal.Approved, Investigational
SecobarbitalThe metabolism of Thiamylal can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThiamylal may increase the hypotensive activities of Selegiline.Approved, Investigational, Vet Approved
SeletracetamThe metabolism of Seletracetam can be increased when combined with Thiamylal.Investigational
SepranoloneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Thiamylal is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Thiamylal.Approved, Vet Approved
SildenafilThe metabolism of Thiamylal can be decreased when combined with Sildenafil.Approved, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Thiamylal.Approved
SomatostatinThe risk or severity of adverse effects can be increased when Somatostatin is combined with Thiamylal.Approved, Investigational
SorafenibThe metabolism of Thiamylal can be decreased when combined with Sorafenib.Approved, Investigational
SotalolThe serum concentration of Sotalol can be decreased when it is combined with Thiamylal.Approved
SpironolactoneThiamylal may increase the hypotensive activities of Spironolactone.Approved
StiripentolThe risk or severity of adverse effects can be increased when Stiripentol is combined with Thiamylal.Approved
StreptokinaseThiamylal may increase the hypotensive activities of Streptokinase.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Thiamylal.Approved, Investigational
SulfadiazineThe metabolism of Thiamylal can be decreased when combined with Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleThe metabolism of Thiamylal can be decreased when combined with Sulfamethoxazole.Approved
SulfisoxazoleThe metabolism of Thiamylal can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Thiamylal.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Thiamylal is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Thiamylal is combined with Sumatriptan.Approved, Investigational
SuvorexantThiamylal may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TalinololThe serum concentration of Talinolol can be decreased when it is combined with Thiamylal.Investigational
TamsulosinThiamylal may increase the hypotensive activities of Tamsulosin.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Thiamylal is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Thiamylal.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Thiamylal.Approved, Investigational
TelmisartanThiamylal may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Thiamylal.Approved, Investigational
TeniposideThe serum concentration of Teniposide can be decreased when it is combined with Thiamylal.Approved
TerazosinThiamylal may increase the hypotensive activities of Terazosin.Approved
TerbutalineThe serum concentration of Terbutaline can be decreased when it is combined with Thiamylal.Approved
TerodilineThe metabolism of Terodiline can be increased when combined with Thiamylal.Experimental
TertatololThe serum concentration of Tertatolol can be decreased when it is combined with Thiamylal.Experimental
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Thiamylal.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Tetracaine.Approved, Vet Approved
TetracyclineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Tetracycline.Approved, Vet Approved
TetrahydropalmatineThe metabolism of Tetrahydropalmatine can be increased when combined with Thiamylal.Investigational
TetrandrineThe metabolism of Tetrandrine can be increased when combined with Thiamylal.Experimental
TetrodotoxinThe risk or severity of adverse effects can be increased when Thiamylal is combined with Tetrodotoxin.Investigational
ThalidomideThiamylal may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Thiamylal.Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Thiamylal.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Thiamylal.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Thiamylal.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Thiamylal.Approved, Investigational
TianeptineThe metabolism of Tianeptine can be increased when combined with Thiamylal.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Thiamylal is combined with Tiapride.Approved, Investigational
TicagrelorThe metabolism of Thiamylal can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Thiamylal can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Tilidine.Experimental
TimololThe serum concentration of Timolol can be decreased when it is combined with Thiamylal.Approved
TioclomarolThe metabolism of Tioclomarol can be increased when combined with Thiamylal.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Thiamylal.Approved, Investigational
TolazolineThiamylal may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideThe metabolism of Thiamylal can be decreased when combined with Tolbutamide.Approved, Investigational
TolcaponeThiamylal may increase the hypotensive activities of Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe metabolism of Tolfenamic Acid can be increased when combined with Thiamylal.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Thiamylal.Approved
TopiroxostatThe metabolism of Thiamylal can be decreased when combined with Topiroxostat.Approved, Investigational
TorasemideThiamylal may increase the hypotensive activities of Torasemide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Thiamylal.Approved, Investigational
TrandolaprilThiamylal may increase the hypotensive activities of Trandolapril.Approved
TranilastThe metabolism of Tranilast can be increased when combined with Thiamylal.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Thiamylal.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Thiamylal.Approved, Investigational
TretinoinThiamylal may increase the hypotensive activities of Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThiamylal may increase the hypotensive activities of Triamterene.Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Thiamylal.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Thiamylal is combined with Tricaine methanesulfonate.Vet Approved
TrichlormethiazideThiamylal may increase the orthostatic hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Thiamylal.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Thiamylal is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Thiamylal.Approved, Vet Approved
TrimebutineThe metabolism of Trimebutine can be increased when combined with Thiamylal.Approved
TrimethadioneThe metabolism of Trimethadione can be increased when combined with Thiamylal.Approved
TrimethoprimThe metabolism of Thiamylal can be decreased when combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe metabolism of Trimipramine can be increased when combined with Thiamylal.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Thiamylal.Approved
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Thiamylal.Approved
UlipristalThe therapeutic efficacy of Ulipristal can be decreased when used in combination with Thiamylal.Approved
ValaciclovirThe serum concentration of Valaciclovir can be decreased when it is combined with Thiamylal.Approved, Investigational
Valproic AcidThe serum concentration of Thiamylal can be increased when it is combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Thiamylal can be decreased when combined with Valsartan.Approved, Investigational
VancomycinThe risk or severity of adverse effects can be increased when Thiamylal is combined with Vancomycin.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Thiamylal is combined with Vecuronium.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Thiamylal is combined with Veralipride.Experimental
VerapamilThiamylal may increase the hypotensive activities of Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Thiamylal.Approved
VinpocetineThe metabolism of Vinpocetine can be increased when combined with Thiamylal.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Thiamylal is combined with Vinyl ether.Experimental
VoriconazoleThe serum concentration of Voriconazole can be decreased when it is combined with Thiamylal.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Vortioxetine.Approved, Investigational
WarfarinThe metabolism of Warfarin can be increased when combined with Thiamylal.Approved
WIN 55212-2The metabolism of WIN 55212-2 can be increased when combined with Thiamylal.Experimental
XenonThe risk or severity of adverse effects can be increased when Thiamylal is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Xylazine.Vet Approved
ZafirlukastThe metabolism of Thiamylal can be decreased when combined with Zafirlukast.Approved, Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Thiamylal.Approved, Illicit, Investigational
ZiconotideThe metabolism of Ziconotide can be increased when combined with Thiamylal.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Thiamylal.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Thiamylal is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Thiamylal is combined with Zolmitriptan.Approved, Investigational
ZolpidemThiamylal may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe metabolism of Zonisamide can be increased when combined with Thiamylal.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Thiamylal.Approved
ZotepineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Zotepine.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Thiamylal.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0015285
KEGG Drug
D06106
KEGG Compound
C07846
PubChem Compound
3032285
PubChem Substance
46506261
ChemSpider
2297298
ChEBI
9536
ChEMBL
CHEMBL440
Therapeutic Targets Database
DAP000684
PharmGKB
PA164746997
Wikipedia
Thiamylal
ATC Codes
N05CB01 — Combinations of barbiturates

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)132-133 °CPhysProp
water solubility49.4 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP3.23HANSCH,C ET AL. (1995)
logS-3.46ADME Research, USCD
pKa7.48SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.0506 mg/mLALOGPS
logP3.11ALOGPS
logP2.92ChemAxon
logS-3.7ALOGPS
pKa (Strongest Acidic)7.2ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area58.2 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity70.64 m3·mol-1ChemAxon
Polarizability26.75 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.5532
Blood Brain Barrier+0.9582
Caco-2 permeable-0.5361
P-glycoprotein substrateNon-substrate0.5169
P-glycoprotein inhibitor IInhibitor0.5544
P-glycoprotein inhibitor IINon-inhibitor0.9368
Renal organic cation transporterNon-inhibitor0.8887
CYP450 2C9 substrateNon-substrate0.8124
CYP450 2D6 substrateNon-substrate0.8589
CYP450 3A4 substrateNon-substrate0.7011
CYP450 1A2 substrateNon-inhibitor0.7869
CYP450 2C9 inhibitorNon-inhibitor0.5555
CYP450 2D6 inhibitorNon-inhibitor0.9131
CYP450 2C19 inhibitorNon-inhibitor0.6101
CYP450 3A4 inhibitorNon-inhibitor0.8138
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8282
Ames testNon AMES toxic0.6521
CarcinogenicityNon-carcinogens0.9047
BiodegradationNot ready biodegradable0.9974
Rat acute toxicity2.7058 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9781
hERG inhibition (predictor II)Non-inhibitor0.8205
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - CI-BGC-MSsplash10-0a4i-0090000000-8766fbc86b0e4f9df12c
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as thiobarbituric acid derivatives. These are organic compounds containing a 2-thioxodihydropyrimidine-4,6(1H,5H)-dione skeleton.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazines
Sub Class
Pyrimidines and pyrimidine derivatives
Direct Parent
Thiobarbituric acid derivatives
Alternative Parents
Diazinanes / Thioureas / Carboxylic acids and derivatives / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Thiobarbiturate / 1,3-diazinane / Thiourea / Azacycle / Carboxylic acid derivative / Organic nitrogen compound / Organic oxygen compound / Organopnictogen compound / Organic oxide / Hydrocarbon derivative
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
barbiturates, organosulfur compound (CHEBI:9536)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Gene Name
GABRA1
Uniprot ID
P14867
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-1
Molecular Weight
51801.395 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Sugimura M, Kitayama S, Morita K, Imai Y, Irifune M, Takarada T, Kawahara M, Dohi T: Effects of GABAergic agents on anesthesia induced by halothane, isoflurane, and thiamylal in mice. Pharmacol Biochem Behav. 2002 May;72(1-2):111-6. [PubMed:11900777]
  4. Whiting PJ: The GABAA receptor gene family: new opportunities for drug development. Curr Opin Drug Discov Devel. 2003 Sep;6(5):648-57. [PubMed:14579514]
  5. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232]
  6. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
  7. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207]
  8. Grasshoff C, Netzhammer N, Schweizer J, Antkowiak B, Hentschke H: Depression of spinal network activity by thiopental: shift from phasic to tonic GABA(A) receptor-mediated inhibition. Neuropharmacology. 2008 Oct;55(5):793-802. doi: 10.1016/j.neuropharm.2008.06.026. Epub 2008 Jun 21. [PubMed:18619475]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Inward rectifier potassium channel activity
Specific Function
This potassium channel is controlled by G proteins. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their...
Gene Name
KCNJ8
Uniprot ID
Q15842
Uniprot Name
ATP-sensitive inward rectifier potassium channel 8
Molecular Weight
47967.455 Da
References
  1. Eguchi S, Kawano T, Oshita S, Nakajo N: [Effects of propofol and thiamylal on nicorandil induced ATP-sensitive potassium channel activities in cultured rat aortic smooth muscle cells]. Masui. 2005 Apr;54(4):364-9. [PubMed:15852621]
  2. Kawano T, Oshita S, Takahashi A, Tsutsumi Y, Tomiyama Y, Kitahata H, Kuroda Y, Nakaya Y: Molecular mechanisms of the inhibitory effects of propofol and thiamylal on sarcolemmal adenosine triphosphate-sensitive potassium channels. Anesthesiology. 2004 Feb;100(2):338-46. [PubMed:14739809]
  3. Tsutsumi Y, Oshita S, Kitahata H, Kuroda Y, Kawano T, Nakaya Y: Blockade of adenosine triphosphate-sensitive potassium channels by thiamylal in rat ventricular myocytes. Anesthesiology. 2000 Apr;92(4):1154-9. [PubMed:10754636]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated potassium channel activity
Specific Function
This receptor is controlled by G proteins. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage ...
Gene Name
KCNJ11
Uniprot ID
Q14654
Uniprot Name
ATP-sensitive inward rectifier potassium channel 11
Molecular Weight
43540.375 Da
References
  1. Kawano T, Oshita S, Takahashi A, Tsutsumi Y, Tomiyama Y, Kitahata H, Kuroda Y, Nakaya Y: Molecular mechanisms of the inhibitory effects of propofol and thiamylal on sarcolemmal adenosine triphosphate-sensitive potassium channels. Anesthesiology. 2004 Feb;100(2):338-46. [PubMed:14739809]
  2. Tsutsumi Y, Oshita S, Kitahata H, Kuroda Y, Kawano T, Nakaya Y: Blockade of adenosine triphosphate-sensitive potassium channels by thiamylal in rat ventricular myocytes. Anesthesiology. 2000 Apr;92(4):1154-9. [PubMed:10754636]
  3. Eguchi S, Kawano T, Oshita S, Nakajo N: [Effects of propofol and thiamylal on nicorandil induced ATP-sensitive potassium channel activities in cultured rat aortic smooth muscle cells]. Masui. 2005 Apr;54(4):364-9. [PubMed:15852621]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Sueyasu M, Fujito K, Shuto H, Mizokoshi T, Kataoka Y, Oishi R: Protein binding and the metabolism of thiamylal enantiomers in vitro. Anesth Analg. 2000 Sep;91(3):736-40. [PubMed:10960410]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Tanaka E, Nakamura T, Inomata S, Honda K: Effects of premedication medicines on the formation of the CYP3A4-dependent metabolite of ropivacaine, 2', 6'-Pipecoloxylidide, on human liver microsomes in vitro. Basic Clin Pharmacol Toxicol. 2006 Feb;98(2):181-3. doi: 10.1111/j.1742-7843.2006.pto_265.x. [PubMed:16445592]

Drug created on June 13, 2005 07:24 / Updated on August 02, 2018 07:53